Illumina, Inc. 2016 Q3 Form 10-Q Summary
Business context and reporting period
Illumina is a global provider of DNA sequencing and array-based technologies serving research, clinical, and applied markets. The filing covers the 13-week quarter and 39-week year-to-date period ended October 2, 2016, compared with the periods ended September 27, 2015. Results include consolidated variable interest entities GRAIL and Helix, which became material for segment reporting in the third quarter.
Key financial metrics
| Metric | Q3 2016 | Q3 2015 | YTD 2016 | YTD 2015 |
|---|---|---|---|---|
| Total revenue | $607.1 million | $550.3 million | $1.779 billion | $1.628 billion |
| Gross profit | $426.2 million | $387.5 million | $1.247 billion | $1.139 billion |
| Gross margin | 70.2% | 70.4% | 70.1% | 69.9% |
| Operating income | $160.7 million | $140.8 million | $444.0 million | $468.8 million |
| Net income attributable to Illumina stockholders | $128.9 million | $118.2 million | $338.9 million | $357.1 million |
| Diluted EPS | $0.87 | $0.79 | $2.27 | $2.39 |
| Cash flow from operations | Not separately provided | Not separately provided | $407.1 million | $419.2 million |
Q3 revenue increased 10%, with consumables revenue rising 23% to $396.4 million and service and other revenue increasing 18% to $93.4 million. Instrument revenue declined 23% to $112.4 million, primarily because of lower high-throughput platform shipments. YTD revenue increased 9%; consumables grew 22%, while instrument revenue declined 20%.
Q3 operating margin was approximately 26.5%, compared with 25.6% in the prior-year quarter. YTD operating margin was approximately 25.0%, compared with 28.8% in the prior-year period. Q3 effective tax rate was 24.2%, versus 10.3% in Q3 2015; the prior-year rate benefited from a $24.8 million discrete tax benefit. The YTD effective tax rate was 24.9%, versus 20.9%.
At October 2, 2016, cash and cash equivalents were $794.7 million and short-term investments were $741.6 million, or approximately $1.5 billion combined. Cash and cash equivalents increased $25.9 million from January 3, 2016. YTD investing cash use was $341.2 million, including $178.4 million of capital expenditures. Financing cash use was $41.2 million, including $113.1 million of share repurchases and $70.5 million of financing-obligation payments.
Outstanding convertible debt consisted of $632.5 million of 0% notes due 2019 and $517.5 million of 0.5% notes due 2021. Net carrying value of long-term debt was $1.037 billion. The 2019 and 2021 notes were not convertible as of October 2, 2016. Management stated that available cash, investments, and operating cash flow should fund capital and operating needs for at least the next 12 months.
Material changes versus the prior comparable period
- Revenue growth was led by sequencing consumables and services, while instrument shipments declined.
- YTD R&D expense increased 30% to $374.5 million, reflecting higher product-development spending and expenses from GRAIL and Helix.
- YTD SG&A expense increased 16% to $436.9 million due to headcount, facilities investment, and outside services.
- YTD operating income declined $24.8 million despite higher gross profit, primarily because operating expenses increased faster than gross profit.
- YTD net income attributable to Illumina stockholders declined 5% because of higher operating expenses and a higher effective tax rate.
- Capital expenditures increased substantially, and property and equipment, net rose to $633.9 million from $342.7 million at January 3, 2016, partly due to facility construction.
- GRAIL and Helix were consolidated; their combined operating loss was $25.1 million in Q3 and $49.7 million YTD. GRAIL had no revenue and remained in development.
Outlook, commentary, risks, contingencies, and unusual items
Management expects continued demand for sequencing technologies and growth in sequencing consumables. Array demand may shift toward lower-complexity, lower-priced products, while some array applications may migrate to sequencing. Management expects operating expenses, including R&D and SG&A, to continue growing and expects the effective tax rate to trend below the U.S. federal statutory rate because of earnings in lower-tax jurisdictions. No specific revenue or earnings guidance was provided in the filing.
Illumina committed $100.0 million to a venture capital fund, callable over ten years; $7.6 million had been contributed or transferred through October 2, 2016. The company also had $236.9 million remaining under its authorized share-repurchase program.
On July 1, 2016, Illumina settled Enzo Life Sciences litigation for $21.0 million. Of this amount, $11.5 million was capitalized as a licensed intangible asset and $9.5 million related to past damages. The company continues to face ordinary-course litigation and states that adverse outcomes could materially affect results, financial condition, or cash flow.
Cash held by GRAIL and Helix totaled $103.6 million and was not available to settle Illumina obligations. Certain noncontrolling interests in GRAIL and Helix may be redeemable for cash after specified future dates, subject to contractual conditions. Build-to-suit lease liabilities increased to $178.3 million from $9.5 million at year-end. The company identified no material changes to previously disclosed risk factors or market risks and reported effective disclosure controls.
Important facts for investors to verify
- Whether consumables growth continues to offset lower instrument revenue and potential migration from arrays to sequencing.
- The sustainability of approximately 70% gross margins as service mix, pricing, product mix, and manufacturing costs change.
- Whether elevated R&D and SG&A spending produces sufficient new-product and market growth.
- The future cash requirements and operating losses of consolidated GRAIL and Helix, including possible noncontrolling-interest redemptions.
- Capital-expenditure commitments, build-to-suit lease obligations, and the company’s ability to maintain liquidity while repurchasing shares.
- Conversion, maturity, and dilution risks associated with the $1.15 billion principal amount of outstanding convertible notes.
- Potential outcomes of pending litigation and the effects of future tax-rate changes or discrete tax items.